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TO THE EDITOR
The presence of recurrent chromosomal
translocations in multiple leukemias and
lymphomas suggests that altered chro-
mosomes have an integral role in tumor
development (Drexler et al., 1995). Iden-
tifying chromosomal translocations has
led to diagnostic, prognostic, and thera-
peutic advances for a variety of hemato-
logic malignancies (Rowley, 2008). The
anaplastic lymphoma kinase (ALK) gene
is translocated in approximately half of
systemic T-cell anaplastic large-cell lym-
phomas (ALCLs), resulting in overexpres-
sion of ALK fusion proteins (Savage
et al., 2008; Feldman et al., 2009). The
search for recurrent translocations in
the remaining half of ALCLs, which are
ALK negative, has led to the discovery
of recurrent translocations involving the
DUSP22–IRF4 locus on 6p25.3 (Feldman
et al., 2011). These recurrent transloca-
tions have been found in both systemic
and primary cutaneous (pc) ALK-negative
ALCLs, as well as rarely in lympho-
matoid papulosis and transformed
mycosis fungoides (Pham-Ledard et al.,
2010; Wada et al., 2011).
Translocations involving 6p25.3 can
have breakpoints in or near either IRF4
or DUSP22, which lie only B40 kb
apart at the extreme telomeric tip of 6p
(Feldman et al., 2009). IRF4 encodes
IFN regulatory factor-4, also known as
multiple myeloma oncogene-1 (MUM1),
a transcription factor expressed in acti-
vated T lymphocytes, plasma cells,
and some B cells (Falini et al., 2000).
DUSP22 encodes a dual-specificity
phosphatase protein that inhibits TCR
signaling and has been proposed as a
possible tumor-suppressor gene (Alonso
et al., 2002). Gene expression studies
have shown that, regardless of whether
the translocation breakpoint involved
DUSP22 or IRF4, DUSP22 expression
was up to 50 times lower in ALCLs with
6p25.3 translocations than in cases with-
out the translocation, whereas IRF4
expression was unchanged (Feldman
et al., 2009). The mechanisms for the
downregulation of DUSP22 expression
remain incompletely understood, as
previous reported cases had transloca-
tions involving only one copy of chromo-
some 6. In this paper, we present three
cases of cutaneous ALCL, classified
according to the WHO/EORTC (World
Health Organization/European Organi-
zation for Research and Treatment of
Cancer) classification system (Willemze
et al., 2005), with at least two copies of
chromosome 6 bearing a 6p25.3 trans-
location and no intact copies of the
normal 6p25.3 allele. These cases indi-
cate at least one mechanism for abo-
lishing DUSP22 expression in T-cell
lymphomas, and provide additional
evidence that DUSP22 may represent a
tumor-suppressor gene, the loss of
which may contribute to the patho-
genesis of cutaneous ALCL.
Case 1
A 54-year-old woman with a history of
pcALCL on her left arm presented with a
50-pound weight loss explained by diet-
ing and a single 2.5 cm ipsilateral axil-
lary lymph node. She had a positron
emission tomography (PET) scan and
bone marrow biopsy that were negative.
There has been no evidence of extra-
cutaneous disease after 2 years without
treatment, effectively excluding sys-
temic ALCL. Histology of the lymph
node showed CD30þ , ALK anaplas-
tic cells infiltrating the paracortical T
zone, sparing of germinal centers, and
sinus infiltration. Immunohistochemistry
revealed atypical cells to be positive for
CD30, CD3, partially for CD15, and
weakly for B-cell lymphoma 2 (Bcl-2).
They were negative for ALK-1, CD4,
CD5, CD8, pankeratin, MelanA,
HBME-1, S100, Cyclin D1, CD20,
CD79A, BCL-6, CD56, and CD57.
This was diagnostic of ALK-negative
ALCL, consistent with spreading from
pcALCL.
Case 2
A 71-year-old man presented with a
nodular forehead lesion. The dermis
was expanded by a proliferation of
medium-sized to large atypical lym-
phoid cells, including ‘‘hallmark’’ cells.
Atypical cells were positive for CD2,
CD3 (weak), CD30, CD45, and TCR-b
(b-F1), and negative for CD5, CD7,
CD8, TIA-1, granzyme B, and ALK. A
single regional lymph node showed
some PET activity that was interpreted
as not suspicious for lymphoma. He had
no evidence of disease 3 months after
presentation.
Case 3
A 79-year-old woman presented with
an isolated skin lesion on the left thigh.
The lesion contained large atypical lym-
phoid cells within the dermis, including
‘‘hallmark’’ cells. Atypical cells were
positive for CD2, CD3, CD30, and
TCR-b (b-F1), and negative for CD4,
CD5, CD7, CD8, TIA-1, granzyme B,
and ALK. Another lesion appeared on
the abdomen 1 month later and was
excised with similar histology. ClinicalAccepted article preview online 21 January 2013
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evaluation, including PET scan, showed
no evidence of systemic disease. She
was without further lesions 5 months
after presentation.
Fluorescence in situ hybridization (FISH)
was performed as described previously,
with minor modifications (Feldman
et al., 2009). For break-apart FISH,
bacterial artificial chromosome (BCA)
DNA corresponding to the DUSP22–
IRF4 locus on 6p25.3 was labeled as
follows: telomeric (red) CTD-3234E6
and CTD-2308G5; centromeric (green)
CTD-3104D10, RP11-963H23, and
RP11-1104N17. For dual-fusion (D-)
FISH to detect t(6;7)(p25.3;q32.3), all
five BACs corresponding to 6p25.3
were labeled red, whereas the
previously reported BACs corres-
ponding to 7q32.3 were labeled green
(Feldman et al., 2011). In one case, the
centromeric 6p25.3 BACs were labeled
red and cohybridized with CEP 6
(D6Z1) labeled in green (Vysis/Abbott
Molecular, Abbott Park, IL).
All cases demonstrated at least two
copies of chromosome 6 bearing a
6p25.3 translocation and no copies of
an intact DUSP22–IRF4 locus, as shown
in Figure 1. In case 1 (Figure 1a), there
were four copies of chromosome 6, two
of which were involved in a balanced
translocation with chromosome 7
[t(6;7)(p25.3;q32.3)], which is the most
common partner locus for 6p25.3 trans-
locations and is seen in 45% of cases
(Feldman et al., 2011). The remaining
two copies of chromosome 6 had
separations of the DUSP22–IRF4 locus
with deletions of the telomeric
fragments of 6p. Although we cannot
exclude the possibility that the
translocation detected in the lymph
node occurred as a ‘‘second hit,’’ we
have never seen this abnormality
acquired over sequential biopsies
from the same patient (Wada et al.,
2011 and AL Feldman, unpublished
data). In case 2 (Figure 1b), there
were two copies of chromosome 6
involving unbalanced translocations
with chromosome 7 [der(6)t(6;7)
(p25.3;q32.3)] with deletions of the
telomeric fragments of 6p. In case 3
(Figure 1c), there were two copies of
chromosome 6 involved by 6p25.3
translocations with an unknown (non-
7q32.3) partner [t(6;?)(p25.3;?)].
The complete absence of an intact
DUSP22–IRF4 locus on 6p25.3 seen in
these three cases represents at least one
mechanism to explain the profound
downregulation of DUSP22 expression
in T-cell lymphomas with 6p25.3 trans-
locations. DUSP22 is a dual-specificity
phosphatase that regulates the c-Jun
N-terminal kinase (JNK) and extracellu-
lar signal–regulated kinase (ERK) mito-
gen-activated protein kinase signaling
pathways, and inhibits TCR signaling
in T cells (Falini et al., 2000). DUSP22
overexpression has been shown to
reduce estrogen receptor activity and
to inhibit estrogen receptor signaling in
breast cancer cells (Sekine et al., 2007).
In chronic lymphocytic leukemia,
DUSP22 expression is associated with
mutated IGVH gene status, which is
associated with improved survival
(Jantus Lewintre et al., 2009). Our
findings suggest that loss of the
DUSP22 allele, if acting as a tumor-
suppressor gene, could contribute to the
pathogenesis of these cases of pcALCL.
Each case demonstrated multiple
copies of the abnormal chromosome 6
involved in 6p25.3 translocations. It is
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Figure 1. Fluorescence in situ hybridization (FISH) results in three cases of primary cutaneous anaplastic large-cell lymphomas (pcALCLs) with biallelic
DUSP22–IRF4 rearrangements. Probe labels correspond to the colors indicated on the image legends; the colors in the schematic diagrams at right correspond to
the t(6;7) dual-fusion FISH (D-FISH) results. No copies of an intact DUSP22–IRF4 locus were seen in any of the cases, as seen from the break-apart probe images.
(a) Case 1 had two balanced t(6;7)(p25.3;q32.3) translocations and two additional copies of chromosome 6 with breakpoints in the DUSP22–IRF4 locus and
deletions of the telomeric fragments of 6p. (b) Case 2 had two unbalanced translocations, der(6)t(6;7)(p25.3;q32.3). (c) Case 3 had two copies of chromosome 6
with 6p25.3 translocations involving an unknown partner.
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not clear whether these multiple alleles
represent separate translocation events
or aneusomy of a previously translo-
cated chromosome. The latter possibility
is favored, given that: (1) the partner
status (7q32.3 or other) was identical in
the allele pairs from each case; (2) two
of the three cases demonstrated aneu-
ploidy; and (3) 6p25.3 translocations
appear to be an early event during
lymphomagenesis, based on our con-
stant finding of this translocation in
initial biopsies from patients with
multiple tumor specimens over time
(AL Feldman, unpublished observation).
In addition to the lack of a normal
copy of the 6p25.3 allele, multiple
copies of the translocations could
have implications on the partner
locus. For example, we previously
reported overexpression of microRNAs
(especially MIR29B1) that reside
near the 7q32.3 breakpoint in ALK-
negative ALCLs with t(6;7)(p25.3;q32.3)
(Feldman et al., 2009).
In summary, we present three cases of
pcALCL with biallelic rearrangements of
6p25.3 and no intact copies of the
DUSP22–IRF4 locus. These cases indi-
cate one mechanism by which both
copies of the DUSP22 gene can be
disrupted or deleted in T-cell lympho-
mas, and provide further evidence that
DUSP22 may represent a tumor-
suppressor gene.
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TO THE EDITOR
Loxosceles spiders are a genus of ara-
chnids, whose bites cause necrotizing
skin lesions. They are distributed world-
wide in temperate and tropical regions.
In Brazil, approximately 10,000 cases
of Loxosceles spider bites are reported
annually. L. intermedia, L. gaucho,
and L. laeta are prevalent in most of
the southern states of Brazil, whereas
L. similis has been described mainly in
the state of Minas Gerais. L. reclusa
and L. deserta cause the majority of
accidents in North America. The
venoms of these species all have similar
biochemical and pharmacological pro-
files (Barbaro et al., 2005; Silvestre
et al., 2005; Chatzaki et al., 2012).
The envenomation, described as
loxoscelism, is characterized by pain,
local edema, and erythema, followed
by dermonecrosis that require weeks to
heal. The genesis of loxoscelism is
attributed to a family of sphingo-
myelinase D enzymes, also known as
Accepted article preview online 25 January 2013
Abbreviations: LPA, lysophosphatidic acid; LPC, lysophosphatidylcholine; LsV, L. similis venom; PLD,
phospholipase D; recLiD1, recombinant L. intermedia dermonecrotic protein 1
CCR Horta et al.
LPA and Loxosceles Venom–Induced Inflammation
1682 Journal of Investigative Dermatology (2013), Volume 133
